Daewoong pharmaceutical Co.,Ltd (069620.KS)
KRW 143800.0
(4.2%)
KRW 143800.0
(4.2%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 469.68 Billion KRW | 5.14% |
| 2022 | 446.71 Billion KRW | 0.23% |
| 2021 | 445.69 Billion KRW | 0.0% |
| 2020 | 445.69 Billion KRW | 13.43% |
| 2019 | 392.93 Billion KRW | 1.57% |
| 2018 | 386.84 Billion KRW | 0.46% |
| 2017 | 385.06 Billion KRW | -2.99% |
| 2016 | 396.91 Billion KRW | 67.58% |
| 2015 | 236.85 Billion KRW | 64.07% |
| 2014 | 144.36 Billion KRW | 236.76% |
| 2013 | 42.86 Billion KRW | 1400.65% |
| 2012 | 2.85 Billion KRW | -91.0% |
| 2011 | 31.72 Billion KRW | -63.47% |
| 2010 | 86.85 Billion KRW | 0.58% |
| 2009 | 86.35 Billion KRW | -24.43% |
| 2008 | 114.27 Billion KRW | 286.02% |
| 2007 | 29.6 Billion KRW | 48.22% |
| 2006 | 19.97 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 505.33 Billion KRW | 7.59% |
| 2024 Q2 | 551.97 Billion KRW | 9.23% |
| 2023 Q4 | 469.68 Billion KRW | 13.76% |
| 2023 FY | 469.68 Billion KRW | 5.14% |
| 2023 Q2 | 412.82 Billion KRW | -6.57% |
| 2023 Q1 | 441.84 Billion KRW | -1.09% |
| 2023 Q3 | 412.88 Billion KRW | 0.01% |
| 2022 FY | 446.71 Billion KRW | 0.23% |
| 2022 Q3 | 448.98 Billion KRW | 0.54% |
| 2022 Q4 | 446.71 Billion KRW | -0.51% |
| 2022 Q2 | 446.59 Billion KRW | 0.5% |
| 2022 Q1 | 444.36 Billion KRW | -0.3% |
| 2021 Q2 | 444.44 Billion KRW | -0.15% |
| 2021 FY | 445.69 Billion KRW | 0.0% |
| 2021 Q1 | 445.11 Billion KRW | -0.13% |
| 2021 Q3 | 444.07 Billion KRW | -0.08% |
| 2021 Q4 | 445.69 Billion KRW | 0.37% |
| 2020 Q2 | 391.44 Billion KRW | -0.12% |
| 2020 Q1 | 391.9 Billion KRW | -0.26% |
| 2020 FY | 445.69 Billion KRW | 13.43% |
| 2020 Q3 | 445.9 Billion KRW | 13.91% |
| 2020 Q4 | 445.69 Billion KRW | -0.05% |
| 2019 Q2 | 392.68 Billion KRW | 0.85% |
| 2019 FY | 392.93 Billion KRW | 1.57% |
| 2019 Q1 | 389.37 Billion KRW | 0.65% |
| 2019 Q4 | 392.93 Billion KRW | 0.21% |
| 2019 Q3 | 392.09 Billion KRW | -0.15% |
| 2018 Q3 | 396.79 Billion KRW | 0.71% |
| 2018 Q1 | 387.38 Billion KRW | 0.6% |
| 2018 FY | 386.84 Billion KRW | 0.46% |
| 2018 Q4 | 386.84 Billion KRW | -2.51% |
| 2018 Q2 | 393.98 Billion KRW | 1.7% |
| 2017 Q4 | 385.06 Billion KRW | -3.28% |
| 2017 FY | 385.06 Billion KRW | -2.99% |
| 2017 Q3 | 398.12 Billion KRW | 0.5% |
| 2017 Q2 | 396.13 Billion KRW | 0.33% |
| 2017 Q1 | 394.85 Billion KRW | -0.52% |
| 2016 Q4 | 396.91 Billion KRW | 18.26% |
| 2016 Q1 | 235.63 Billion KRW | -0.52% |
| 2016 Q2 | 336.52 Billion KRW | 42.82% |
| 2016 FY | 396.91 Billion KRW | 67.58% |
| 2016 Q3 | 335.64 Billion KRW | -0.26% |
| 2015 FY | 236.85 Billion KRW | 64.07% |
| 2015 Q2 | 146.7 Billion KRW | 2.55% |
| 2015 Q3 | 237.58 Billion KRW | 61.95% |
| 2015 Q1 | 143.06 Billion KRW | -0.9% |
| 2015 Q4 | 236.85 Billion KRW | -0.31% |
| 2014 Q2 | 43.72 Billion KRW | 2.51% |
| 2014 Q3 | 43.77 Billion KRW | 0.12% |
| 2014 FY | 144.36 Billion KRW | 236.76% |
| 2014 Q4 | 144.36 Billion KRW | 229.78% |
| 2014 Q1 | 42.65 Billion KRW | -0.5% |
| 2013 FY | 42.86 Billion KRW | 1400.65% |
| 2013 Q3 | 3.01 Billion KRW | 11.01% |
| 2013 Q2 | 2.71 Billion KRW | -2.1% |
| 2013 Q4 | 42.86 Billion KRW | 1320.25% |
| 2013 Q1 | 2.77 Billion KRW | -2.77% |
| 2012 Q1 | - KRW | 0.0% |
| 2012 Q4 | 2.85 Billion KRW | 0.0% |
| 2012 FY | 2.85 Billion KRW | -91.0% |
| 2011 Q1 | 52.08 Billion KRW | 0.0% |
| 2011 FY | 31.72 Billion KRW | -63.47% |
| 2011 Q3 | 29.97 Billion KRW | -41.82% |
| 2011 Q2 | 51.52 Billion KRW | -1.09% |
| 2010 Q1 | 86.35 Billion KRW | -2.03% |
| 2010 FY | 86.85 Billion KRW | 0.58% |
| 2010 Q2 | 90.39 Billion KRW | 4.67% |
| 2010 Q3 | 86.98 Billion KRW | -3.77% |
| 2009 Q2 | 108.93 Billion KRW | 0.0% |
| 2009 Q4 | 88.14 Billion KRW | -1.15% |
| 2009 Q3 | 89.17 Billion KRW | -18.14% |
| 2009 FY | 86.35 Billion KRW | -24.43% |
| 2008 Q3 | 94.17 Billion KRW | 77.1% |
| 2008 Q2 | 53.17 Billion KRW | 0.0% |
| 2008 Q4 | 104.1 Billion KRW | 10.55% |
| 2008 FY | 114.27 Billion KRW | 286.02% |
| 2007 FY | 29.6 Billion KRW | 48.22% |
| 2007 Q2 | 19.98 Billion KRW | 0.0% |
| 2007 Q4 | 15 Billion KRW | -24.97% |
| 2007 Q3 | 19.99 Billion KRW | 0.05% |
| 2006 FY | 19.97 Billion KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -1091.878% |
| Dong-A Socio Holdings Co., Ltd. | 691.88 Billion KRW | 32.115% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | -451.534% |
| Ildong Pharmaceutical Co., Ltd. | 217.84 Billion KRW | -115.609% |
| Ildong Holdings Co., Ltd. | 382.06 Billion KRW | -22.935% |
| Hana Pharm Co., Ltd. | 26.53 Billion KRW | -1670.189% |
| Kukje Pharma Co., Ltd. | 30.66 Billion KRW | -1431.812% |
| Yuhan Corporation | 230.07 Billion KRW | -104.148% |
| Dong-A ST Co., Ltd. | 406.7 Billion KRW | -15.485% |
| SAMSUNG PHARM. Co., LTD. | 595.48 Million KRW | -78774.33% |
| Hanall Biopharma Co.,Ltd | 1.29 Billion KRW | -36294.776% |
| Dong Sung Bio Pharm.Co.,Ltd. | 43.27 Billion KRW | -985.405% |
| MYUNGMOON Pharm co.,Ltd | 90.48 Billion KRW | -419.091% |
| Samjin Pharmaceuticals Co., Ltd. | 118.63 Billion KRW | -295.897% |
| CKD Bio Corp. | 146.92 Billion KRW | -219.673% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -1091.878% |
| REYON Pharmaceutical Co., Ltd. | 225.05 Billion KRW | -108.699% |
| Aprogen pharmaceuticals,Inc. | 180.99 Billion KRW | -159.499% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | -175.83% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -917.705% |
| Hyundai Pharmaceutical Co., Ltd. | 39.2 Billion KRW | -1098.027% |
| Yungjin Pharm. Co., Ltd. | 66.88 Billion KRW | -602.259% |
| HANDOK Inc. | 300.01 Billion KRW | -56.556% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -1091.878% |
| Kwang Dong Pharmaceutical Co., Ltd. | 235.64 Billion KRW | -99.322% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | -175.83% |
| Yuhan Corporation | 230.07 Billion KRW | -104.148% |
| Jeil Pharma Holdings Inc | 173.03 Billion KRW | -171.447% |
| Hanmi Pharm. Co., Ltd. | 572.86 Billion KRW | 18.011% |
| Chong Kun Dang Pharmaceutical Corp. | 219.76 Billion KRW | -113.723% |
| Suheung Co., Ltd. | 467.85 Billion KRW | -0.391% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | -175.83% |
| Chong Kun Dang Holdings Corp. | 468.03 Billion KRW | -0.353% |
| Ilsung Pharmaceuticals Co., Ltd. | 238.12 Million KRW | -197142.384% |
| JW Holdings Corporation | 554.58 Billion KRW | 15.309% |
| Samil Pharmaceutical Co.,Ltd | 175.87 Billion KRW | -167.05% |
| Jeil Pharmaceutical Co.,Ltd | 84.96 Billion KRW | -452.795% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -917.705% |
| Daewon Pharmaceutical Co., Ltd. | 146.04 Billion KRW | -221.593% |
| Korea United Pharm Inc. | 40.33 Billion KRW | -1064.345% |
| Whan In Pharm Co.,Ltd. | 632.02 Million KRW | -74214.308% |
| Dongwha Pharm.Co.,Ltd | 48.25 Billion KRW | -873.333% |
| Boryung Corporation | 204.21 Billion KRW | -129.995% |
| Bukwang Pharmaceutical Co., Ltd. | 79.38 Billion KRW | -491.641% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | -451.534% |
| JW Lifescience Corporation | 46.31 Billion KRW | -914.158% |